Osteosarcoma Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Osteosarcoma remains an active clinical development field. The competitive center of gravity is moving toward biomarker-defined populations, rational combinations, earlier treatment lines and evidence that can survive active-comparator scrutiny. The PatSnap evidence set used here contains 335 matched trial records and 365 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07695311 | Botensilimab + Balstilimab | Phase 1; Not yet recruiting | The Case Comprehensive Cancer Center | United States | Safety of EWSR1 immunotherapy, measured by number of participants with grade 4 immunotherapy-related adverse events (Up to 6 months); Safety of combination therapy (EWSR1 immunotherapy + botensilimab + balstilimab), measured by number of participants with grade 3 drug related adverse events lasting greater than 1 week (Up to 6 months) | 2029-10-01 |
| NCT07685405 | Intervention not normalized | Not Applicable; Recruiting | Istituto Ortopedico Rizzoli | Italy | characterisation of circulating biomarkers (at baseline (time 0); before surgery; after 6 months from surgery) | 2028-04-01 |
| NCT07662239 | Intervention not normalized | Not Applicable; Not yet recruiting | Dana-Farber Cancer Institute, Inc. | United States | Triage Tool Completion Rate (2 weeks); Referral Completion Rate (Within 2 months of EXCEEDS completion) | 2026-08-28 |
| NCT07658768 | Indocyanine Green | Early Phase 1; Not yet recruiting | Abramson Cancer Center | Geography not listed | Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) (1 year) | 2027-05-01 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- Overall survival analysis of a heavily pretreated population of patients with bone sarcomas treated with mecbotamab vedotin, a conditionally binding ADC targeting AXL. (Phase 1/2): the indexed record reports DCR = 50.0 %; DCR = 50.0 %; DCR = 100.0 %.
- A phase 1b study of xaluritamig (a STEAP1 x CD3 T-cell engager) in pediatric, adolescent, and adult patients with relapsed/refractory (R/R) Ewing sarcoma. (Phase 1): the indexed record reports AE = The most common treatment-related AEs (TRAEs) were anemia (52%), fatigue (46%), and headache (43%)..
- Efficacy and safety analysis of anlotinib combined with etoposide plus ifosfamide in the treatment of children and adolescents with pulmonary metastatic osteosarcoma. (Not Applicable): the indexed record reports ORR = 15.0 %; ORR = 22.2 %.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Botensilimab (Phase 3; CTLA4), Balstilimab (NDA/BLA; PD-1), Indocyanine Green (Approved; STT3B). Company & Deal Intelligence records identify sponsor context for The Case Comprehensive Cancer Center, Istituto Ortopedico Rizzoli, Dana-Farber Cancer Institute, Inc., Abramson Cancer Center. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Prospective biomarker thresholds that predict benefit rather than simply confirm target presence.
- Randomized sequencing evidence after prior targeted therapy, immunotherapy or antibody–drug conjugates.
- Endpoints that connect response depth with durability, quality of life and overall survival.
- Geographically broader development programs with harmonized molecular testing.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Osteosarcoma has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
